Targeted Lipid Profiling Discovers Plasma Biomarkers of XXXX .

@entity1545 @entity1 @entity131 @entity64 @entity63 @entity19 @entity2248 @entity35 @entity130
Prior efforts to identify a blood biomarker of @entity1545 have relied almost exclusively on proteins; however their low levels at early time points and poor correlation with @entity130 have been limiting. Lipids, on the other hand, are the most abundant molecules in the brain and readily cross the blood-brain barrier. We previously showed that certain sphingolipid (SL) species are highly specific to the brain. Here we examined the feasibility of using @entity2248 as biomarkers for @entity131 . A @entity35 model of @entity131 ( @entity131 ) and a @entity19 model of @entity64 were used to identify candidate SL species though our mass-spectrometry based lipid profiling approach. Plasma samples collected after @entity131 in the @entity35 showed large increases in many circulating @entity2248 following injury, and larger lesions produced proportionately larger increases. Plasma samples collected 24 hours after @entity64 in @entity19 similarly revealed a large increase in many @entity2248 . We constructed an SL score (sum of the two SL species showing the largest relative increases in the @entity19 @entity64 model) and then evaluated the diagnostic value of this score on a small sample of @entity1 (n = 14) who presented with @entity64 . @entity1 with @entity64 had significantly higher SL scores than @entity1 found to have non- @entity64 causes of their symptoms. The SL score correlated with the volume of @entity63 brain tissue. These results demonstrate the feasibility of using lipid biomarkers to diagnose @entity1545 . Future studies will be needed to further characterize the diagnostic utility of this approach and to transition to an assay method applicable to clinical settings.
